3 Pharmaceutical Stocks to Sell Now

by Portfolio Grader | March 8, 2013 8:00 am

3 Pharmaceutical Stocks to Sell Now

This week, the overall grades of three Pharmaceutical stocks are lower, according to the Portfolio Grader[1] database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Corcept Therapeutics (NASDAQ:CORT[2]) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CORT also gets F’s. The stock price has dropped 12% over the past month, worse than the 2% increase the Nasdaq has seen over the same period of time. To get an in-depth look at CORT, get Portfolio Grader’s complete analysis of CORT stock[3].

VIVUS Inc.’s (NASDAQ:VVUS[4]) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The stock also gets an F in Equity. Investors seem to agree with the downgrade and have pushed down the share price 17% over the past month. As of March 8, 2013, 23.9% of outstanding VIVUS Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock[5].

Cempra Holdings LLC (NASDAQ:CEMP[6]) experiences a ratings drop this week, going from last week’s C to a D. Cempra, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage pharmaceutical company, which focuses on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and skin and skin st… The stock gets F’s in Equity and Cash Flow. For a full analysis of CEMP stock, visit Portfolio Grader[7].

Louis Navellier’s proprietary Portfolio Grader[8] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[9].

Endnotes:
  1. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  2. CORT: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CORT
  3. To get an in-depth look at CORT, get Portfolio Grader’s complete analysis of CORT stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CORT
  4. VVUS: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=VVUS
  5. For more information, get Portfolio Grader’s complete analysis of VVUS stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=VVUS
  6. CEMP: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CEMP
  7. For a full analysis of CEMP stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CEMP
  8. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  9. here: http://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: http://investorplace.com/2013/03/3-pharmaceutical-stocks-to-sell-now-cort-vvus-cemp-2/
Short URL: http://invstplc.com/1fv9D14